The intact antibody of human immunoglobulin (IgG) is composed of the fragment for antigen
binding (Fab) and the crystallizable fragment (Fc) for binding of Fcγ receptors. Among the …

BACKGROUND:: Bevacizumab is a recombinant humanized monoclonal antibody that was
approved by the US Food and Drug Administration (FDA) in February 2004 for use as part of …

Background No effective therapeutic options for patients with unresectable imatinib-resistant
gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo …

Abstract Bevacizumab (Avastin™, Genentech) is a humanized monoclonal antibody
targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in …

'Vascular endothelial growth factor-A (VEGF-A) blockade has been recently validated as an
effective strategy for the inhibition of new blood vessel growth in cancer and ocular …

Angiogenesis is important in the growth and progression of solid tumours. The main pro-
angiogenic factor, namely vascular endothelial growth factor (VEGF), also known as …

Aims To report the rate of intraocular pressure (IOP) elevation associated with repeated
intravitreal injections of antivascular endothelial growth factor (VEGF) agents and to …

Radiation therapy forms one of the building blocks of the multi-disciplinary management of
patients with brain tumors. Improved survival following radiation therapy may come with a …

BACKGROUND. Sunitinib malate is a novel multitargeted receptor tyrosine kinase inhibitor
with established efficacy in the treatment of metastatic renal cell carcinoma and imatinib …

PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization
(NV) over a period of 3 months. DESIGN: Prospective, nonrandomized, masked …